A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 105 participants.

Also called NCT06716424

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose other
Phase
Phase 4
Enrolled
  • 105 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06716424
  • WHO UTN U1111-1303-3494
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
India (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06716424. Allocation not applicable; no masking; primary purpose other. Start 2025-01-06 (actual); primary completion 2026-06-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus
Intervention (Drug)
iGlarLixi (insulin glargine/lixisenatide)
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct06716424
Content hash
dcf439d00050ffcfc3f0e188d104bb67bee3ceff6f7f10d4dc9e03caddb5dc8c